Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IcoSema vs Insulin Glargine in Type 2 Diabetes (COMBINE 4)
NCT06269107Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 3, randomised trial of icosema in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycated haemoglobin at 40 weeks. Started Feb 2024; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06269107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06269107.